Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | GRN | P28799 | 1/20 | 0.49 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GALR3 | O60755 | 1/20 | 0.43 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | BRAF | P15056 | 2/20 | 0.42 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18196052 | 0.86 | KDM4E (0.50) | LMNAKDM4EHTTHSD17B10RAB9A | |
| SCHEMBL1865416 | 0.79 | RAB9A (0.52) | LMNAKDM4EHTTHSD17B10RAB9A | |
| SCHEMBL7985728 | 0.72 | KDM4E (0.67) | LMNAKDM4EHTTHSD17B10RAB9A | |
| SCHEMBL1903709 | 0.72 | MAPT (0.68) | LMNAKDM4EHSD17B10RAB9ANPC1 | |
| SCHEMBL350954 | 0.71 | KDM4E (0.65) | LMNAKDM4EHTTRAB9AGRN | |
| SCHEMBL1897017 | 0.70 | BRAF (0.58) | KDM4ERAB9ANPSR1GRNSORT1 | |
| SCHEMBL27572930 | 0.69 | F2 (0.52) | LMNAKDM4EHTTRAB9ANPC1 | |
| SCHEMBL350765 | 0.69 | GRN (0.71) | LMNAKDM4ERAB9AGRNSORT1 | |
| SCHEMBL13753933 | 0.69 | KDM4E (0.61) | LMNAKDM4EHTTHSD17B10RAB9A | |
| Hydrochloric Acid SCHEMBL6312227 | 0.69 | KDM4E (0.56) | LMNAKDM4EHTTHSD17B10RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10751495-B2 | Patient interface | KONINKLIJKE PHILIPS N.V. (NL) | 2020-08-25 | — | — | US | disclosed |
| US-20110105597-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2011-05-05 | — | — | US | disclosed |
| US-20110105597-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2011-05-05 | — | — | US | disclosed |
| US-20100280036-A1 | Modulation of Pathogenicity | QUONOVA, LLC | 2010-11-04 | — | — | US | disclosed |
| US-20100280036-A1 | Modulation of Pathogenicity | QUONOVA, LLC | 2010-11-04 | — | — | US | disclosed |
| US-20100280036-A1 | Modulation of Pathogenicity | QUONOVA, LLC | 2010-11-04 | — | — | US | disclosed |
| EP-1478364-B1 | SELECTIVE ANTIBACTERIAL AGENTS | QUONOVA LLC (US) | 2009-09-16 | — | — | EP | disclosed |
| US-20090076012-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2009-03-19 | — | — | US | disclosed |
| US-20090076012-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2009-03-19 | — | — | US | disclosed |
| US-20090076012-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2009-03-19 | — | — | US | disclosed |
| US-20080182878-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-07-31 | — | — | US | disclosed |
| US-20080176938-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-07-24 | — | — | US | disclosed |
| US-20080176938-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-07-24 | — | — | US | disclosed |
| US-20080176938-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-07-24 | — | — | US | disclosed |
| US-7335779-B2 | Modulation of pathogenicity | QUONOVA, LLC (US) | 2008-02-26 | — | — | US | disclosed |
| US-7335779-B2 | Modulation of pathogenicity | QUONOVA, LLC (US) | 2008-02-26 | — | — | US | disclosed |
| US-7335779-B2 | Modulation of pathogenicity | QUONOVA, LLC (US) | 2008-02-26 | — | — | US | disclosed |
| EP-1478364-A2 | SELECTIVE ANTIBACTERIAL AGENTS | 4SC AG (DE) | 2004-11-24 | — | — | EP | disclosed |
| US-20040063765-A1 | Modulation of pathogenicity | 4 SC AG (DE) | 2004-04-01 | — | — | US | disclosed |
| WO-2003039549-A2 | SELECTIVE ANTIBACTERIAL AGENTS | 4SC AG (DE) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076012-A1 | Modulation of pathogenicity | NR4A1, NR4A2, NR4A3 | LMNA 3658/4885KDM4E 3680/4885HTT 4218/4885 |
| US-20110105597-A1 | Modulation of pathogenicity | NR4A1, NR4A2, NR4A3 | LMNA 3684/4885KDM4E 3715/4885HTT 4231/4885 |
| US-20100280036-A1 | Modulation of Pathogenicity | NR4A1, NR4A2, NR4A3 | LMNA 3684/4885KDM4E 3715/4885HTT 4231/4885 |
| US-20080182878-A1 | Modulation of pathogenicity | NR4A1, NR4A2, MSR1 | LMNA 3656/4885KDM4E 3712/4885HTT 4229/4885 |
| US-20080176938-A1 | Modulation of pathogenicity | NR4A1, NR4A2, NR4A3 | LMNA 3839/4885KDM4E 3704/4885HTT 4216/4885 |
| US-20040063765-A1 | Modulation of pathogenicity | NR1H4, NR4A1, MSR1 | LMNA 2977/4885KDM4E 3783/4885HTT 4502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.